Updated Sep 2, 2026
/Trump and Rubio seal Venezuela oil deal covering 65 billion barrels across 17 fields/Bond rout gathers pace as borrowing costs hit multi-decade highs/Van Jones calls El-Sayed's total Israel arms embargo 'insane,' cites Obama legacy on defense/Memecoin buys on Robinhood Wallet and Fomo coded as "digital media," sidestepping card-network crypto rules/Caring Brands (CABR) Closes $4.6 Million Initial Series B Preferred Stock Private Placement/Sanmar Group takes majority stake in AltEons Energy to back 1.5GW India pipeline/Trump and Rubio seal Venezuela oil deal covering 65 billion barrels across 17 fields/Bond rout gathers pace as borrowing costs hit multi-decade highs/Van Jones calls El-Sayed's total Israel arms embargo 'insane,' cites Obama legacy on defense/Memecoin buys on Robinhood Wallet and Fomo coded as "digital media," sidestepping card-network crypto rules/Caring Brands (CABR) Closes $4.6 Million Initial Series B Preferred Stock Private Placement/Sanmar Group takes majority stake in AltEons Energy to back 1.5GW India pipeline

Novo's Wegovy Pill Still Leads the GLP-1 Pill Market as Lilly's Foundayo Launches

Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Foundayo, Eli Lilly's GLP-1 pill, according to MarketWatch.

By Corinne Ashford2 min readNVOLLY
Share